IL128690A - Cyclic amine derivatives and pharmaceutical compositions containing the same - Google Patents
Cyclic amine derivatives and pharmaceutical compositions containing the sameInfo
- Publication number
- IL128690A IL128690A IL12869097A IL12869097A IL128690A IL 128690 A IL128690 A IL 128690A IL 12869097 A IL12869097 A IL 12869097A IL 12869097 A IL12869097 A IL 12869097A IL 128690 A IL128690 A IL 128690A
- Authority
- IL
- Israel
- Prior art keywords
- alkoxy
- alkyl
- substituted
- optionally substituted
- halo
- Prior art date
Links
- -1 Cyclic amine Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 3
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 abstract 2
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP22650796 | 1996-08-28 | ||
| PCT/JP1997/002990 WO1998008811A1 (fr) | 1996-08-28 | 1997-08-28 | Derives cycliques d'amines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL128690A0 IL128690A0 (en) | 2000-01-31 |
| IL128690A true IL128690A (en) | 2003-03-12 |
Family
ID=16846212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12869097A IL128690A (en) | 1996-08-28 | 1997-08-28 | Cyclic amine derivatives and pharmaceutical compositions containing the same |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6087379A (de) |
| EP (1) | EP0934928B1 (de) |
| KR (1) | KR100417887B1 (de) |
| CN (1) | CN1192019C (de) |
| AT (1) | ATE279389T1 (de) |
| AU (1) | AU715531B2 (de) |
| CA (1) | CA2263983C (de) |
| CZ (1) | CZ300295B6 (de) |
| DE (1) | DE69731218T2 (de) |
| ES (1) | ES2229382T3 (de) |
| HU (1) | HU228082B1 (de) |
| IL (1) | IL128690A (de) |
| NO (1) | NO312955B1 (de) |
| NZ (1) | NZ334389A (de) |
| PT (1) | PT934928E (de) |
| RU (1) | RU2163596C2 (de) |
| WO (1) | WO1998008811A1 (de) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100567950B1 (ko) * | 1998-02-27 | 2006-04-05 | 상꾜 가부시키가이샤 | 환상 아미노화합물 |
| DE60032520T2 (de) * | 2000-06-08 | 2007-10-04 | Kaneka Corp. | Verfahren zur herstellung von sulfonsäureestern |
| NZ547401A (en) * | 2003-11-28 | 2008-06-30 | Sankyo Co | Cyclic amine derivative having heteroaryl ring |
| JP2008504279A (ja) * | 2004-06-24 | 2008-02-14 | インサイト・コーポレイション | アミド化合物およびその医薬としての使用 |
| MXPA06014574A (es) | 2004-06-24 | 2007-03-12 | Incyte Corp | Piperidinas n-sustituidas y su uso como farmaceuticos. |
| US20090306059A1 (en) * | 2005-05-13 | 2009-12-10 | Tomio Kimura | Cyclic amine derivative having substituted alkyl group |
| TW200720252A (en) * | 2005-05-27 | 2007-06-01 | Sankyo Co | Cyclic amine derivative having substituted alkyl group |
| EP1940399A2 (de) * | 2005-08-19 | 2008-07-09 | Eli Lilly & Company | Verfahren zur behandlung von gefässerkrankungen |
| KR101044559B1 (ko) * | 2007-09-20 | 2011-06-28 | 국제약품공업주식회사 | 티올 화합물의 산부가염 및 그의 제조방법 |
| CN102428069B (zh) * | 2009-04-02 | 2014-04-02 | 盐野义制药株式会社 | 丙烯酰胺化合物及其用途 |
| DE202009018503U1 (de) | 2009-04-30 | 2011-11-16 | Saint-Gobain Sekurit Deutschland Gmbh & Co. Kg | Infrarotstrahlung abschirmendes, für sichtbares Licht transparentes Laminat mit einem für Infrarotstrahlung durchlässigen optischen Fenster |
| WO2013024376A1 (en) * | 2011-08-16 | 2013-02-21 | Mahesh Kandula | Compositions and methods for the treatment of atherothrombosis |
| WO2014037832A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of epilepsy and neurological diseases |
| US9399634B2 (en) | 2012-05-07 | 2016-07-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of depression |
| EP2847158A4 (de) | 2012-05-07 | 2015-12-30 | Cellix Bio Private Ltd | Zusammensetzungen und verfahren zur behandlung neuromuskulärer erkrankungen und neurodegenerativer erkrankungen |
| CA2872975A1 (en) | 2012-05-07 | 2013-11-14 | Cellixbio Private Limited | Compositions and methods for the treatment of neurological disorders |
| US9403826B2 (en) | 2012-05-08 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory disorders |
| US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
| WO2013168025A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of blood clotting disorders |
| US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
| US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
| US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
| US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| WO2013167997A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
| US9315461B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
| WO2013168000A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of severe pain |
| WO2013168011A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of chronic pain |
| US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
| WO2013168001A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| WO2013168015A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of asthma and allergy |
| SG11201407318UA (en) | 2012-05-10 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of metabolic syndrome |
| WO2013168012A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
| US9233161B2 (en) | 2012-05-10 | 2016-01-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological conditions |
| WO2013168033A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neurologic diseases |
| JP2015518855A (ja) | 2012-05-23 | 2015-07-06 | セリックスビオ プライヴェート リミテッド | 粘膜炎の治療のための組成物および方法 |
| WO2013175347A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
| JP2015518854A (ja) | 2012-05-23 | 2015-07-06 | セリックスビオ プライヴェート リミテッド | 多発性硬化症の治療のための組成物および方法 |
| US9492409B2 (en) | 2012-05-23 | 2016-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| JP6202287B2 (ja) | 2012-05-23 | 2017-09-27 | セリックスビオ プライヴェート リミテッド | 炎症性腸疾患の治療のための組成物及び方法 |
| US9434729B2 (en) | 2012-05-23 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
| US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| WO2014020480A2 (en) | 2012-08-03 | 2014-02-06 | Mahesh Kandula | Compositions and methods for the treatment migraine and neurologic diseases |
| US9624168B2 (en) | 2012-09-06 | 2017-04-18 | Cellix Bio Private Limited | Compositions and methods for the treatment inflammation and lipid disorders |
| SG11201407325YA (en) | 2012-09-08 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for treatment of inflammation and lipid disorders |
| WO2014118649A2 (en) * | 2013-01-19 | 2014-08-07 | Mahesh Kandula | Compositions and methods for the treatment of cardiovascular diseases |
| US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| EP3004049B1 (de) | 2013-06-04 | 2018-09-05 | Cellixbio Private Limited | Zusammensetzungen und verfahren zur behandlung von diabetes und prädiabetes |
| US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
| EP3240779B1 (de) | 2014-09-26 | 2020-10-28 | Cellixbio Private Limited | Zusammensetzungen und verfahren zur behandlung von epilepsie- und lipidstörungen |
| EP3201168B1 (de) | 2014-09-29 | 2020-03-18 | Cellix Bio Private Limited | Verbindungen und zusammensetzungen zur behandlung multipler sklerose |
| CA2965449C (en) | 2014-10-27 | 2020-11-10 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
| US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
| US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
| US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
| US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
| US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
| US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
| EP3242869B1 (de) | 2015-01-06 | 2021-10-27 | Cellixbio Private Limited | Zusammensetzungen und verfahren zur behandlung von entzündungen und schmerzen |
| CN106554368A (zh) * | 2015-09-25 | 2017-04-05 | 陕西合成药业股份有限公司 | 噻吩并吡啶类衍生物及其制备方法和用途 |
| CN106554302A (zh) * | 2015-09-25 | 2017-04-05 | 陕西合成药业股份有限公司 | 噻吩并吡啶类衍生物及其制备方法和用途 |
| CN106554303A (zh) * | 2015-09-25 | 2017-04-05 | 陕西合成药业股份有限公司 | 噻吩并吡啶类衍生物及其制备方法和用途 |
| CN105481760A (zh) * | 2016-01-20 | 2016-04-13 | 天津药物研究院有限公司 | 衍生化的替比格雷活性代谢产物的制备方法 |
| CN111484446A (zh) * | 2020-04-02 | 2020-08-04 | 北京翼方生物科技有限责任公司 | 氯吡格雷代谢活性体二硫衍生物、其制备方法及医药用途 |
| AU2021317436A1 (en) * | 2020-07-29 | 2023-02-23 | Shanghai Curegene Pharmaceutical Co., Ltd. | Antiplatelet drugs and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2215948B1 (de) * | 1973-02-01 | 1976-05-14 | Centre Etd Ind Pharma | |
| FR2495156A1 (fr) * | 1980-11-28 | 1982-06-04 | Sanofi Sa | Derives de la thieno-pyridinone, leur procede de preparation et leur application therapeutique |
| FR2530247B1 (fr) * | 1982-07-13 | 1986-05-16 | Sanofi Sa | Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique |
| FR2576901B1 (fr) * | 1985-01-31 | 1987-03-20 | Sanofi Sa | Nouveaux derives de l'acide a-(oxo-2 hexahydro-2,4,5,6,7,7a thieno (3,2-c) pyridyl-5) phenyl acetique, leur procede de preparation et leur application therapeutique |
| FR2623810B2 (fr) * | 1987-02-17 | 1992-01-24 | Sanofi Sa | Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant |
| FI101150B (fi) * | 1991-09-09 | 1998-04-30 | Sankyo Co | Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi |
| EP0623120A1 (de) * | 1992-01-21 | 1994-11-09 | Glaxo Group Limited | Piperidinessigsäure-Derivate, als Inhibitoren der fibrinogen-abhängigen Blutplättchen-Aggregation |
| DE59408453D1 (de) * | 1993-04-23 | 1999-08-12 | Hoechst Ag | Pyrido-pyrimidindione, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO1995007691A1 (en) * | 1993-09-17 | 1995-03-23 | Brigham And Women's Hospital | Use of nitric oxide-adducts to prevent thrombosis on artificial and vascular surfaces |
-
1997
- 1997-07-28 NZ NZ334389A patent/NZ334389A/en not_active IP Right Cessation
- 1997-08-28 DE DE69731218T patent/DE69731218T2/de not_active Expired - Lifetime
- 1997-08-28 EP EP97937814A patent/EP0934928B1/de not_active Expired - Lifetime
- 1997-08-28 CZ CZ0063099A patent/CZ300295B6/cs not_active IP Right Cessation
- 1997-08-28 WO PCT/JP1997/002990 patent/WO1998008811A1/ja active IP Right Grant
- 1997-08-28 KR KR10-1999-7001526A patent/KR100417887B1/ko active IP Right Grant
- 1997-08-28 AT AT97937814T patent/ATE279389T1/de active
- 1997-08-28 HU HU9903762A patent/HU228082B1/hu not_active IP Right Cessation
- 1997-08-28 IL IL12869097A patent/IL128690A/xx not_active IP Right Cessation
- 1997-08-28 CN CNB971992452A patent/CN1192019C/zh not_active Expired - Lifetime
- 1997-08-28 PT PT97937814T patent/PT934928E/pt unknown
- 1997-08-28 AU AU40312/97A patent/AU715531B2/en not_active Expired
- 1997-08-28 ES ES97937814T patent/ES2229382T3/es not_active Expired - Lifetime
- 1997-08-28 RU RU99104152/04A patent/RU2163596C2/ru active
- 1997-08-28 CA CA002263983A patent/CA2263983C/en not_active Expired - Lifetime
-
1999
- 1999-02-25 US US09/257,818 patent/US6087379A/en not_active Expired - Lifetime
- 1999-02-26 NO NO19990951A patent/NO312955B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2263983C (en) | 2006-03-21 |
| NO990951D0 (no) | 1999-02-26 |
| EP0934928B1 (de) | 2004-10-13 |
| HU228082B1 (en) | 2012-10-29 |
| NO312955B1 (no) | 2002-07-22 |
| DE69731218T2 (de) | 2005-06-30 |
| CN1235596A (zh) | 1999-11-17 |
| US6087379A (en) | 2000-07-11 |
| NO990951L (no) | 1999-04-27 |
| CA2263983A1 (en) | 1998-03-05 |
| RU2163596C2 (ru) | 2001-02-27 |
| ATE279389T1 (de) | 2004-10-15 |
| AU715531B2 (en) | 2000-02-03 |
| PT934928E (pt) | 2004-12-31 |
| KR20000035839A (ko) | 2000-06-26 |
| HUP9903762A3 (en) | 2001-02-28 |
| ES2229382T3 (es) | 2005-04-16 |
| CZ63099A3 (cs) | 1999-07-14 |
| IL128690A0 (en) | 2000-01-31 |
| EP0934928A1 (de) | 1999-08-11 |
| WO1998008811A1 (fr) | 1998-03-05 |
| CZ300295B6 (cs) | 2009-04-15 |
| NZ334389A (en) | 2001-05-25 |
| CN1192019C (zh) | 2005-03-09 |
| HUP9903762A2 (hu) | 2000-02-28 |
| AU4031297A (en) | 1998-03-19 |
| KR100417887B1 (ko) | 2004-02-11 |
| EP0934928A4 (de) | 2001-05-09 |
| DE69731218D1 (de) | 2004-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL128690A (en) | Cyclic amine derivatives and pharmaceutical compositions containing the same | |
| DE69420564D1 (de) | Immunsuppressive und antiallergische verbindungen; z.b. n-(3-oxohexanoyl)-homoserinlacton | |
| MY127718A (en) | Dolastatin 10 derivatives. | |
| DE69628466D1 (de) | Zwischenverbindungen zur Herstellung von neunen Pyridoncarbonsäurederivate oder deren Salzen | |
| ES8306093A1 (es) | Procedimiento de preparacion de derivados aminoalcoil heterociclicos farmaceuticamente activos. | |
| PL295030A1 (en) | Method of obtaining substituted derivatives of 2-cyclohexan-1-yl amine | |
| DE60101000D1 (de) | N-heterocyclische derivate als nos inhibitoren | |
| PE20001297A1 (es) | Antibioticos cetolidos carbamato y carbazato | |
| AR012489A1 (es) | Tiofenopiridinas antagonistas del factor de liberacion de corticotropina. procedimiento para su preparacion, el uso de las mismas en la preparacionde un medicamento, composicion farmaceutica que las comprende, procedimiento para la preparacion de dicha composicion, un compuesto intermediario y | |
| ATE180781T1 (de) | Kristallines tiagabinehydrochlorid-monohydrat, seine herstellung und verwendung | |
| ES2091359T3 (es) | Nuevo compuesto peptidico y un procedimiento para su preparacion. | |
| IL140070A0 (en) | Benzamide derivatives and pharmaceutical compositions containing the same | |
| IL108695A (en) | Pharmaceutical composition comprising polyamine derivatives and some such novel compounds | |
| FI961507A (fi) | Antrasyklinonijohdannaiset ja niiden käyttö amyloidoosissa | |
| DE59400211D1 (de) | Fungizide Mischungen | |
| HUP9902992A3 (en) | Alpha-amino acid amides, preparation thereof and pharmaceutical compositions containing them | |
| DE69330601D1 (de) | Serotoninergische ergolin derivate | |
| GR3015797T3 (en) | Amides of 1-(alkoxybenzyl)piperazines, processes for their preparation and pharmaceutical compositions containing them. | |
| ATE281452T1 (de) | 4-amino-2-ureido-pyrimidin-5-carbonsäureamide, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung | |
| DE60000125D1 (de) | 7-Oxo-2,3,7,14-tetrahydro-1H-benzo[b]pyrano[3,2-h]acridincarboxylatderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen | |
| MXPA04011363A (es) | Nuevos derivados acil hidrazino del tiofeno, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion. | |
| HUP9903383A2 (hu) | Poliol-szukcinátok és ilyen vegyületeket tartalmazó gyógyszerkészítmények | |
| HUP9902678A2 (hu) | Protein kináz-C inhibitor hatású, halogénatommal szubsztituált bisz(indol)-maleinmid-származékok, valamint ezeket tartalmazó gyógyászati készítmények |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXP | Patent expired |